Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) EBT Margin: 2013-2017

Historic EBT Margin for Soleno Therapeutics (SLNO) over the last 3 years, with Jun 2017 value amounting to -296,500.00%.

  • Soleno Therapeutics' EBT Margin fell 18175000.00% to -296,500.00% in Q2 2017 from the same period last year, while for Jun 2017 it was -926.06%, marking a year-over-year increase of 48697.00%. This contributed to the annual value of 76,125.54% for FY2024, which is N/A change from last year.
  • As of Q2 2017, Soleno Therapeutics' EBT Margin stood at -296,500.00%, which was down 57,168.59% from -517.74% recorded in Q1 2017.
  • Soleno Therapeutics' 5-year EBT Margin high stood at 295.07% for Q2 2014, and its period low was -296,500.00% during Q2 2017.
  • For the 3-year period, Soleno Therapeutics' EBT Margin averaged around -43,087.60%, with its median value being -1,370.24% (2015).
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 1,007,813bps in 2016, then tumbled by 18,175,000bps in 2017.
  • Over the past 5 years, Soleno Therapeutics' EBT Margin (Quarterly) stood at 280.17% in 2013, then slumped by 10,063bps to 179.54% in 2014, then tumbled by 163,136bps to -1,451.82% in 2015, then skyrocketed by 80,588bps to -645.95% in 2016, then crashed by 18,175,000bps to -296,500.00% in 2017.
  • Its EBT Margin stands at -296,500.00% for Q2 2017, versus -517.74% for Q1 2017 and -645.95% for Q4 2016.